95 related articles for article (PubMed ID: 22609269)
1. Bevacizumab therapy may contribute to irradiation deferral in patients with breast cancer and with central nervous system metastases: findings of a case series.
Kountourakis P; Dokou A; Kardara E; Kaltsas S; Doufexis D; Tzovaras A; Mourgela S; Ardavanis A
Clin Breast Cancer; 2012 Aug; 12(4):282-6. PubMed ID: 22609269
[No Abstract] [Full Text] [Related]
2. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.
Labidi SI; Bachelot T; Ray-Coquard I; Mosbah K; Treilleux I; Fayette J; Favier B; Galy G; Blay JY; Guastalla JP
Clin Breast Cancer; 2009 May; 9(2):118-21. PubMed ID: 19433393
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer.
Cassier PA; Ray-Coquard I; Sunyach MP; Lancry L; Guastalla JP; Ferlay C; Gomez F; Curé H; Lortholary A; Claude L; Blay JY; Bachelot T
Cancer; 2008 Nov; 113(9):2532-8. PubMed ID: 18780315
[TBL] [Abstract][Full Text] [Related]
4. Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer.
Altundag K; Altundag O; Atik MA; Morandi P; Gunduz M
Breast; 2005 Oct; 14(5):425. PubMed ID: 16216749
[No Abstract] [Full Text] [Related]
5. [Clinical analysis of 67 patients with brain metastases from breast cancer].
He J; Feng FY; Xing PY; Wang XY; Zhang P
Ai Zheng; 2005 Dec; 24(12):1527-30. PubMed ID: 16351807
[TBL] [Abstract][Full Text] [Related]
6. [Perspectives in antineoplastic therapy of breast cancer with brain metastasis].
Moiseenko VM; Barishpol'skaia IuV; Orlova RV; Protsenko SA; Ermakova NA; Mikhaĭlichenko TD; Semenova AI; Korytova LI; Zhabina RM; Gonta EV
Vopr Onkol; 2004; 50(2):250-2. PubMed ID: 15176232
[No Abstract] [Full Text] [Related]
7. Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis.
Bartsch R; Fromm S; Rudas M; Wenzel C; Harbauer S; Roessler K; Kitz K; Steger GG; Weitmann HD; Poetter R; Zielinski CC; Dieckmann K
Radiother Oncol; 2006 Sep; 80(3):313-7. PubMed ID: 16959347
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal trastuzumab: dose matters.
Hofer S; Mengele K; Stemmler HJ; Schmitt M; Pestalozzi B
Acta Oncol; 2012 Sep; 51(7):955-6. PubMed ID: 22524214
[No Abstract] [Full Text] [Related]
9. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.
Niwińska A; Murawska M; Pogoda K
Cancer; 2010 Sep; 116(18):4238-47. PubMed ID: 20549816
[TBL] [Abstract][Full Text] [Related]
10. Brain metastases in breast cancer: prognostic factors and management.
Lee SS; Ahn JH; Kim MK; Sym SJ; Gong G; Ahn SD; Kim SB; Kim WK
Breast Cancer Res Treat; 2008 Oct; 111(3):523-30. PubMed ID: 17990100
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico].
Arce-Salinas C; Lara-Medina FU; Alvarado-Miranda A; Castañeda-Soto N; Bargalló-Rocha E; Ramírez-Ugalde MT; Pérez-Sánchez V; Rivera L; Gambo-Vignole C; Santamaría-Galicia J; Nieves-Casas RI; Morán-Muñoz H; Mohar-Betancourt A
Rev Invest Clin; 2012; 64(1):9-16. PubMed ID: 22690524
[TBL] [Abstract][Full Text] [Related]
13. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
14. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Unal OU; Mert AG; Bilici M; Ozkan M; Elkiran ET; Yaman S; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Urakci Z; Buyukberber S
Oncology; 2012; 83(3):141-50. PubMed ID: 22814315
[TBL] [Abstract][Full Text] [Related]
15. Comment on: incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
Errante D; Bernardi D; Bianco A; Salvagno L
Acta Oncol; 2007; 46(4):565-6. PubMed ID: 17497328
[No Abstract] [Full Text] [Related]
16. Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: first long time results from a clinical study.
Johansson B; Karlsson L; Liljegren G; Hardell L; Persliden J
Radiother Oncol; 2009 Jan; 90(1):30-5. PubMed ID: 18410975
[TBL] [Abstract][Full Text] [Related]
17. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
Niwińska A; Tacikowska M; Murawska M
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1134-9. PubMed ID: 19932944
[TBL] [Abstract][Full Text] [Related]
18. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
Montemurro F; Aglietta M
Cancer; 2005 Mar; 103(6):1314-5; author reply 1315. PubMed ID: 15674855
[No Abstract] [Full Text] [Related]
19. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
[No Abstract] [Full Text] [Related]
20. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
